Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia

被引：28

作者：

Au, WY

Lam, CCK

Chim, CS

Pang, AWK

Kwong, YL

机构：

[1] Queen Mary Hosp, Univ Dept Med, Hong Kong, Hong Kong, Peoples R China

[2] Queen Mary Hosp, Univ Dept Pathol, Hong Kong, Hong Kong, Peoples R China

来源：

LEUKEMIA RESEARCH | 2005年 / 29卷 / 10期

关键词：

alemtuzumab; pure red cell aplasia;

D O I：

10.1016/j.leukres.2005.02.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1213 / 1215

页数：3

共 9 条

[1] Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis [J].